ATXA Therapeutics - Blackrock

ATXA Therapeutics Ltd is a spin-out company from University College Dublin with a mission to develop clinical trials and secure marketing authorization for novel treatments to address Pulmonary Arterial Hypertension (PAH). Led by Professor Therese Kinsella, the company was established in 2015 after two decades of research and €15 million of grant funding. They have been supported by grants from Enterprise Ireland and Science Foundation Ireland which have enabled them to create a range of small molecule drugs targeting diseases like thrombosis/cardiovascular, oncology, anti-inflammatory and PAH.

ATXA's team is composed of experts in cardiovascular and cancer biology, platelet biology, cellular and molecular biology, protein biology, pathological and histopathological techniques, digital  

Show more

pathology, biostatistics and drug discovery. Their goal is to develop therapies that provide better treatment options and hope to PAH patients, which are superior to the current standard of care.